• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Gyre Therapeutics Inc.

    5/9/25 4:30:37 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GYRE alert in real time by email

    Unavailable

    Get the next $GYRE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GYRE

    DatePrice TargetRatingAnalyst
    10/10/2025$16.00Buy
    Jefferies
    8/26/2025$18.00Buy
    H.C. Wainwright
    3/11/2025Outperform
    Noble Capital Markets
    More analyst ratings

    $GYRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Weng Dan

    4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

    8/26/25 4:09:36 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Weng Dan

    3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

    8/26/25 4:03:35 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Zhang Ping

    4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

    8/7/25 8:00:41 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GYRE
    SEC Filings

    View All

    Gyre Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

    9/10/25 9:00:50 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

    8/22/25 7:05:42 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Gyre Therapeutics Inc.

    10-Q - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

    8/11/25 5:07:32 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GYRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Gyre Therapeutics with a new price target

    Jefferies initiated coverage of Gyre Therapeutics with a rating of Buy and set a new price target of $16.00

    10/10/25 8:38:16 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Gyre Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Gyre Therapeutics with a rating of Buy and set a new price target of $18.00

    8/26/25 8:17:41 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Noble Capital Markets initiated coverage on Gyre Therapeutics

    Noble Capital Markets initiated coverage of Gyre Therapeutics with a rating of Outperform

    3/11/25 10:02:24 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GYRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

    SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals), has completed patient enrollment in the 52-week Phase 3 clinical trial of its Class 1 drug, Pirfenidone capsules, for the treatment of pneumoconiosis. A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-controlled trial being conducted at 18 clinical research centers across China. The trial is desig

    10/15/25 7:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

    SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it will be presenting results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent that inhibits hepatic stellate cell (HSC) activation and promotes HSC apoptosis, for the treatment of liver fibrosis in chronic hepatitis B, at The Liver Meeting® 2025, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting® 2025 is being held November 7-10, 2

    10/14/25 7:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 at 12:30 p.m. ET. To register in advance for the presentation webcast, sign up here. The live webcast of the presentation will be also available on the Events and Presentations page of Gyre's website. A webcast replay will also be accessible following the live session. About Gyre Therapeutics Gyre Therapeut

    9/5/25 4:05:00 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GYRE
    Leadership Updates

    Live Leadership Updates

    View All

    Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

    SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to its Board of Directors (the "Board") effective August 18, 2025. Dr. Weng has served as President and Chief Executive Officer of Medelis, Inc., a specialty oncology contract research organization ("CRO"), since 2018. From 2013 to 2017, he served as Chairman, President, and Chief Executive Officer of EPS International Holding Co., a subsidiary of EPS Holdings, Inc., a global CRO where he oversaw sig

    8/22/25 7:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

    SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the "Board") as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre's majority indirectly owned subsidiary in the People's Republic of China ("PRC"), to focus on other responsibilities at GNI Grou

    1/6/25 7:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

    SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

    8/8/24 4:05:00 PM ET
    $BDTX
    $GYRE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $GYRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Gyre Therapeutics Inc.

    SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

    9/6/24 8:31:07 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Gyre Therapeutics Inc.

    SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

    9/6/24 8:15:45 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GYRE
    Financials

    Live finance-specific insights

    View All

    Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

    Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025Received IND approval from China's National Medical Products Administration ("NMPA") for a new indication of pirfenidone to treat radiation-induced lung injury ("RILI"), with or without immune-related pneumonitis ("CIP"), marking Gyre's first entry into oncology supportive care spaceInitiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialistsNin

    5/9/25 6:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full

    3/17/25 4:15:00 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

    Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced f

    11/13/24 6:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care